Topical diacerein for epidermolysis bullosa: A randomized controlled pilot study

45Citations
Citations of this article
53Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Blistering in epidermolysis bullosa simplex type Dowling-Meara (EBS-DM) is associated with an inflammatory phenotype, which can be disrupted by diacerein in vitro. In this pilot study we hypothesized, that a topical formulation of diacerein 1% reduces blistering. Five patients initially applied diacerein underneath both armpits. Then, each participant received 1% diacerein-cream for one armpit, and placebo for the other (randomized withdrawal). The number of blisters was reduced significantly (left: -78%; right: -66% of baseline) within two weeks and remained significantly below the initial level even during withdrawal in four patients. These findings point to a relevant effect of diacerein and provide important information for a confirmative study. © 2013 Wally et al.; licensee BioMed Central Ltd.

Cite

CITATION STYLE

APA

Wally, V., Kitzmueller, S., Lagler, F., Moder, A., Hitzl, W., Wolkersdorfer, M., … Bauer, J. W. (2013). Topical diacerein for epidermolysis bullosa: A randomized controlled pilot study. Orphanet Journal of Rare Diseases, 8(1). https://doi.org/10.1186/1750-1172-8-69

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free